DELVE INTO AFRICAN WEALTH
DON'T MISS A BEAT
Subscribe now
Skip to content

Australian billionaire Andrew Forrest's family backs peanut allergy shot that doubled tolerance

A Melbourne biotech backed by Andrew Forrest's family says a monthly injection more than doubled the amount of peanut allergic children could safely eat.

Australian billionaire Andrew Forrest's family backs peanut allergy shot that doubled tolerance
Andrew Forrest

Table of Contents

A Melbourne biotech backed by the family office of Australian billionaire Andrew Forrest says a monthly injection more than doubled the amount of peanut that allergic children could eat without a reaction, in a mid-stage trial that could set up a larger study.

Aravax Pty Ltd. said on Nov. 12 that its experimental therapy, PVX108, met the main goal of a Phase 2 trial in 71 children aged 4 to 11 across 14 sites in the U.S. and Australia. After 12 months of monthly injections at the higher dose, the maximum amount of peanut the children could tolerate rose 2.4-fold from the start of the study, compared with 1.2-fold for those given a placebo.

Of the children on the higher dose, 39.4% could tolerate a cumulative 443 milligrams of peanut protein or more, against 16.7% on placebo. Reactions also became milder: 67% of reactions at each child's original trigger dose were graded zero or mild, compared with 35% in the placebo group.

No treatment-related allergic reactions, including anaphylaxis, or serious side effects were reported. The most common side effects were reactions at the injection site. Six months after treatment stopped, a further food challenge showed the benefit held or improved, which the company said points to a possible lasting change in the disease.

"PVX108 is the first therapy designed to precisely target the root cause of peanut allergy," Chief Executive Officer Pascal Hickey said.

Brian Vickery, chief of allergy and immunology at Children's Healthcare of Atlanta, who presented the results at the American College of Allergy, Asthma and Immunology meeting in Phoenix on Nov. 14, said that if larger studies confirm them, the findings "would represent a significant leap forward for the food allergy field."

The Forrest stake

Aravax was spun out of Monash University in 2015. It raised A$20 million ($13.8 million) in late 2022 in a round backed by Brandon Capital and Tenmile, the health technology investment firm set up that year by Tattarang, the private investment group of Forrest and his wife, Nicola. That money funded the Phase 2 study. Its other investors include Novartis Venture Fund, Innovation Victoria, Uniseed and pension fund UniSuper.

The U.S. Food and Drug Administration granted PVX108 fast track status in August, a designation meant to speed review of drugs for serious conditions. The drug uses short synthetic fragments of peanut proteins designed to retrain the immune system without triggering the antibodies behind severe reactions. Of the 68 children who completed the trial, 59 have joined a 12-month open-label extension, with results expected in the second half of 2027.

Peanut allergy affects about 2% of people in Western countries, and the market for treatments has been estimated at $4 billion a year by 2027.

Forrest, 64, built his fortune as the founder and chairman of iron ore miner Fortescue Ltd. and is one of Australia's richest people. Through Tattarang and the Minderoo Foundation, he and Nicola Forrest have put money into health research, clean energy and food production.

Figures were converted at A$1.45 to the dollar.

The intelligence satisfies curiosity. The paid briefings satisfy strategy.

Every Monday, Elite subscribers receive an Investor Memo breaking down the deal, the structure and the positioning behind the week's most consequential African wealth story — the kind of analysis that doesn't appear anywhere else.

Twice a month, a Wealth Intelligence brief profiles a single billionaire's holdings, cash flows and expansion pipeline in detail no public source matches.

→ Executive ($25/mo): Daily newsletter + Deep-Dive Reports

→ Elite ($75/mo): Everything above + Investor Memos + Wealth Intelligence + Quarterly Analyst Briefings

Subscribe now

Latest

}}